Long-term intraocular pressure-lowering efficacy and safety of ripasudil-brimonidine fixed-dose combination for glaucoma and ocular hypertension: a multicentre, open-label, phase 3 study
Graefe's Archive for Clinical and Experimental Ophthalmology · 2024
DOI: 10.1007/s00417-024-06388-y ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Graefe's Archive for Clinical and Experimental Ophthalmology, 2024. Verfasst von Hidenobu Tanihara und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Biei Municipal Hospital, 3-8-35 Naka-machi, Biei Town, Kamikawa-gun, Hokkaido, 071-0207, Japan. tanihara@pearl.ocn.ne.jp. Hauptthemen laut MEDLINE: Intraocular Pressure, Ocular Hypertension, Sulfonamides, Isoquinolines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kowa Company.
Abstract (Originalsprache)
Purpose
To evaluate the long-term efficacy and safety of ripasudil-brimonidine fixed-dose combination (RBFC), a new intraocular pressure (IOP)-lowering medication for glaucoma and ocular hypertension (OHT).
Methods
This prospective, multicentre (23 sites in Japan), open-label study enrolled patients with primary open-angle glaucoma (POAG), OHT or exfoliative glaucoma and assigned them to one of four combination therapy cohorts, based on previous treatment(s) received: prostaglandin (PG) analogue (Cohort 1); PG analogue and beta-adrenoceptor blocker (β-blocker) (Cohort 2); PG analogue, β-blocker and carbonic anhydrase inhibitor (Cohort 3); or other/no treatment (Cohort 4). After a ≥ 4-week screening period, eligible patients received twice-daily RBFC for 52 weeks in addition to the treatments they were already receiving. Efficacy was assessed by change in IOP from baseline through week 52. Adverse events and adverse drug reactions (ADRs) were monitored throughout.
Results
In total, 179 patients from Cohort 1 ( n = 48), Cohort 2 ( n = 44), Cohort 3 ( n = 41) and Cohort 4 ( n = 46) entered the RBFC treatment period. For all cohorts, mean IOP was significantly reduced at 11:00 (2 h after instillation of RBFC) through week 52 with the changes from baseline at week 52 of − 2.7 to − 4.1 mmHg across cohorts; all p < 0.001. Common ADRs were conjunctival hyperaemia (58%), allergic conjunctivitis (18%) and blepharitis (17%), most of which were mild in severity.
Conclusion
These data demonstrated the long-term efficacy and safety of RBFC, both alone and in combination with other anti-glaucoma agents. RBFC may offer a new treatment option for the long-term management of glaucoma and OHT.
Trial registration
Japan Registry of Clinical Trials Identifier: jRCT2080225063. Date of registration 17 February 2020.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Biei Municipal Hospital, 3-8-35 Naka-machi, Biei Town, Kamikawa-gun, Hokkaido, 071-0207, Japan. tanihara@pearl.ocn.ne.jp.
- Prof. Kazuo Iwata Memorial Kaijin Glaucoma Center, Kaiya Eye Clinic, Shizuoka, Japan.
- Department of Ophthalmology, The University of Tokyo, Tokyo, Japan.
- Department of Biomedical Engineering, Faculty of Life and Medical Sciences, Doshisha University, Kyoto, Japan.
- Department of Ophthalmology, Tsukazaki Hospital, Hyogo, Japan.
- Pharmaceutical Clinical Development Management Department, Kowa Company, Ltd., Tokyo, Japan.
Förderung
- Kowa Company
Zitieren
APA
Tanihara, H., Yamamoto, T., Aihara, M., Koizumi, N., Fukushima, A., Kawakita, K., Kojima, S., Nakamura, T., Suganami, H., & K-232 Clinical Study Group (2024). Long-term intraocular pressure-lowering efficacy and safety of ripasudil-brimonidine fixed-dose combination for glaucoma and ocular hypertension: a multicentre, open-label, phase 3 study. Graefe's Archive for Clinical and Experimental Ophthalmology. https://doi.org/10.1007/s00417-024-06388-y
Vancouver
Tanihara H, Yamamoto T, Aihara M, Koizumi N, Fukushima A, Kawakita K, et al. Long-term intraocular pressure-lowering efficacy and safety of ripasudil-brimonidine fixed-dose combination for glaucoma and ocular hypertension: a multicentre, open-label, phase 3 study. Graefe's Archive for Clinical and Experimental Ophthalmology. 2024. doi:10.1007/s00417-024-06388-y
BibTeX
@article{Tanihara2024,
author = {Tanihara, Hidenobu and Yamamoto, Tetsuya and Aihara, Makoto and Koizumi, Noriko and Fukushima, Atsuki and Kawakita, Koji and Kojima, Satoshi and Nakamura, Toka and Suganami, Hideki and K-232 Clinical Study Group, K-232 Clinical Study Group},
title = {Long-term intraocular pressure-lowering efficacy and safety of ripasudil-brimonidine fixed-dose combination for glaucoma and ocular hypertension: a multicentre, open-label, phase 3 study},
journal = {Graefe's Archive for Clinical and Experimental Ophthalmology},
year = {2024},
doi = {10.1007/s00417-024-06388-y}
}
EUVIMED